Télécharger le texte intégral

More documents

Recommendations

Info

Annexe 1 : Article publié dans « Alimentary Pharmacology & Therapeutics » sur la prévalence et les facteurs associés à la stéatose hépatique chez les patients co-infectés VIH- VHC et monoinfectés par le VHC, appariés
Alimentary Pharmacology & Therapeutics Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype L. CASTÉRA*, , M.A.LOKOà, B.LEBAIL§,P.COFFIEà, V. DE LEDINGHEN*, P. TRIMOULET–, M. WINNOCKà, F.DABISà, D. NEAU** & THE GROUPE D’EPIDÉMIOLOGIE CLINIQUE DU SIDA EN AQUITAINE (GECSA) 1 *Department of Hepatology, Hôpital Haut Lévêque, Centre Hospitalier Universitaire (CHU) Bordeaux, Pessac, France; Department of Hepatology, Hopital St André, CHU Bordeaux, Bordeaux, France; àINSERM U593 ISPED, Université Victor Segalen Bordeaux-2, Bordeaux, France; §Department of Pathology, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France; –Department of Virology, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France; **Department of Infectious Diseases, Hôpital Pellegrin, CHU Bordeaux; Bordeaux, France Correspondence to: Dr L. Castera, Service d’Hépato- Gastroenterologie, C.H.U. de Bordeaux, Hôpital Haut Lévêque, Avenue Magellan, 33604 Pessac, France. E-mail: laurent.castera@ chu-bordeaux.fr 1 Composition of the GECSA in charge of the ANRS CO3 Aquitaine Cohort is presented in the Appendix. Publication data Submitted 26 July 2007 First decision 19 August 2007 Resubmitted 10 September 2007 Accepted 24 September 2007 SUMMARY Background Significance of steatosis in HIV-HCV coinfection remains controversial. Aim To compare the prevalence and predictors of hepatic steatosis between HIV-HCV and HCV patients matched for steatosis known determinants. Methods A total of 564 HCV-naive patients undergoing liver biopsy were studied: 137 with HIV-HCV coinfection and 427 with HCV monoinfection, among whom 137 were matched for age, gender, body mass index and HCV genotype. Results Steatosis of any grade (67.1% vs. 41.6%, P < 0.0001), mixed steatosis (55.4% vs. 21.1%, P < 0.0001), severe histological activity (A2-A3: 78.1% vs. 55.5%, P < 0.0001) and severe fibrosis (F3-F4: 33.1% vs. 15.3%, P < 0.0001) were significantly more common in coinfected than in matched monoinfected patients. In multivariate analysis, steatosis was associated only with severe histological activity [odds ratio (OR): 3.1 (95% CI: 1.3–7.1)] in coinfected patients and with elevated body mass index [OR; 1.3 (1.1–1.5)], HCV genotype 3 [OR: 5.6 (2.3–13.9)], severe histological activity [OR: 3.1 (1.3–7.3)] and severe fibrosis [OR: 4.7 (1.3–17.3)] in monoinfected patients. Conclusions Steatosis is significantly more common and severe in HIV-HCV coinfected than in HCV monoinfected French patients, even after matching for body mass index and HCV genotype. Steatosis is associated only with severe histological activity in coinfected patients and with previously reported factors in monoinfected patients, thus suggesting different underlying mechanisms. Aliment Pharmacol Ther 26, 1489–1498 ª 2007 The Authors 1489 Journal compilation ª 2007 Blackwell Publishing Ltd doi:10.1111/j.1365-2036.2007.03533.x
Page 2 and 3:
Université Victor Ségalen Bordeau
Page 4 and 5:
Table des matières Table des mati
Page 6 and 7:
Table des tableaux Liste des tablea
Page 8 and 9:
Introduction INTRODUCTION Selon l
Page 10 and 11:
Introduction Cette thèse se propos
Page 12 and 13:
Chapitre 1 : Etat actuel des connai
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 83 and 84:
Chapitre 2 : Présentation des coho
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Chapitre 3 : Présentation des rés
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140: Chapitre 3 : Présentation des rés
Page 175 and 176: Conclusion CONCLUSION L’étude de
Page 177 and 178: Références REFERENCES 1. INVS. Nu
Page 179 and 180: Références 53. Farrell GC, Larter
Page 181 and 182: Références 96. Eyster ME, Alter H
Page 183 and 184: Références 141. Sulkowski MS, Tho
Page 185 and 186: Références 189. Gilmore IT, Burro
Page 187 and 188: Références 237. Lambert J, Halfon
Page 189: Liste des publications Liste des pu
Page 193 and 194: HEPATIC STEATOSIS IN HIV-HCV AND MA
Page 201 and 202: Annexe 2 : Article publié dans «A
Page 203 and 204: 1974 Loko et al. reason. The accura
Page 205 and 206: 1976 Loko et al. Table 3. Diagnosti
Page 207 and 208: 1978 Loko et al. those published in
Page 209 and 210: 1980 Loko et al. 36. Sebastiani G,
Page 211 and 212: TITLE Analysis of discordant result
Page 213 and 214: INTRODUCTION Chronic hepatitis C vi
Page 215 and 216: PATIENTS AND METHODS Patients Patie
Page 217 and 218: Gilbert's disease, drug-induced hyp
Page 219 and 220: RESULTS Characteristics of the pati
Page 221 and 222: 91%, and APRI in 9%. Lastly, in the
Page 223 and 224: In our study, the lowest discordanc
Page 225 and 226: Otherwise, in patient receiving ata
Page 227 and 228: References 1. Sherman KE, Rouster S
Page 229 and 230: 25. Castera L, Vergniol J, Foucher
Page 231 and 232: Table 1 : Characteristics of HIV-HC
Page 233 and 234: 100% 90% 80% 70% 60% 72% 85% 89% Fi
Page 235 and 236: saquinavir 0.7 (0.3-2.0) 0.57 fosam
Page 237 and 238: saquinavir 1.6 (0.7-3.7) 0.30 fosam
Page 239 and 240: lopinavir/r 1.2 (0.5-2.4) 0.70 NRTI
Page 241 and 242:
Composition of the ANRS CO13 HEPAVI
Page 243 and 244:
Annexe 4: Résumé du protocole de
Page 245 and 246:
PRINCIPAUX CORRESPONDANTS Promoteur
Page 247 and 248:
RESUME PROTOCOLE ANRS CO13 - HEPAVI
Page 249 and 250:
Suivi « cirrhose » (répondeur ou
Page 251 and 252:
ANRS CO 13 HEPAVIH version janvier
Page 253 and 254:
Page 255:
show all

Télécharger le texte intégral

Create successful ePaper yourself

Delete template?

Save as template?